New drug ALC-2203 aims to soothe bronchitis cough

NCT ID NCT07061925

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested whether the experimental drug ALC-2203 can reduce symptoms of acute bronchitis, like cough and chest pain. 169 adults with moderate to severe symptoms took either ALC-2203, an active comparator, or a placebo for 7 days. Researchers measured changes in a symptom score to see if the drug works better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ALC-2203

What this could lead to

If successful, this could lead to a new treatment option to reduce cough and other bronchitis symptoms faster.

What could go wrong

This is an early Phase 2 dose-finding trial with only 169 participants, so results may not confirm effectiveness or safety for wider use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE BRONCHITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Konkuk University Medical Center

    Seoul, 05030, South Korea